Eli Lilly participated in a series B round for the cardiorenal treatment specialist that will support clinical drug trials, boosting its overall funding to $193m.

US-based cardiorenal treatment developer CinCor Pharma received $143m on Tuesday in a series B round that included Lilly Asia Ventures, a venture capital firm sponsored by pharmaceutical firm Eli Lilly. Growth equity firm General Atlantic Led the round, which included Perceptive Advisors, BVF Partners, VenBio Partners, Omega Funds, RTW Investments, Adage Capital Management, Rock Springs…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.